Skip to main
PYPD
PYPD logo

PolyPid (PYPD) Stock Forecast & Price Target

PolyPid (PYPD) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

PolyPid Ltd is a clinical-stage biopharmaceutical company focused on developing its proprietary PLEX drug delivery technology, aiming to address surgical site infections through its flagship product, D-PLEX100, which has shown promising results in late-stage clinical trials. The recent agreement with shareholders will secure $26.7 million in funding, enabling the company to schedule a pre-NDA meeting with the FDA and potentially file for D-PLEX100's approval in the first half of 2026. This influx of capital, coupled with the positive efficacy observed in trials, positions PolyPid well for future growth and regulatory advancement.

Bears say

The analysis of PolyPid Ltd's financial outlook reflects concerns over the potential failure of its product candidates to deliver statistically significant results in clinical studies, which poses a substantial risk to the perceived value of the company. Furthermore, even if clinical trials are successful, there remains uncertainty regarding regulatory approvals from domestic and foreign agencies, which could further diminish the company's value. In addition, complications associated with patent procedures raise further concerns about potential revenue erosion that is anticipated to begin in 2036, contributing to an overall negative outlook on PolyPid's stock.

PolyPid (PYPD) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of PolyPid and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PolyPid (PYPD) Forecast

Analysts have given PolyPid (PYPD) a Strong Buy based on their latest research and market trends.

According to 4 analysts, PolyPid (PYPD) has a Strong Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PolyPid (PYPD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.